| Characteristic | Total | Survivors | Non-survivors | p-value |
---|---|---|---|---|---|
Gender | Male | 17 | 12 | 5 | 0.29 |
Female | 5 | 5 | 0 | Â | |
Race | White or Caucasian | 17 | 13 | 4 | 1 |
Black or African American | 2 | 2 | 0 | Â | |
Other | 3 | 2 | 1 | Â | |
Age | Median (IQR) | 62.5 (42–66.5) | 61 (38.5–65) | 65 (62.5–76) | 0.085 |
Etiology | Ischemic | 6 | 2 | 4 | 0.009 |
Non-Ischemic | 16 | 15 | 1 | Â | |
Diabetes | Diabetic | 7 | 6 | 1 | 1 |
Non-Diabetic | 15 | 11 | 4 | Â | |
INTERMACS | 1 (Critical cardiogenic shock) | 2 | 1 | 1 | 0.23 |
2 (Progressive decline) | 12 | 10 | 2 | Â | |
3 (Stable, but inotrope dependent) | 7 | 6 | 1 | Â | |
4 (Resting symptoms) | 1 | 0 | 1 | Â | |
MCS Device | HeartMate II | 13 | 11 | 2 | 0.25 |
HeartWare | 1 | 1 | 0 | Â | |
HeartMate II, CentriMag | 4 | 2 | 2 | Â | |
TAH | 1 | 1 | 0 | Â | |
PVAD | 2 | 2 | 0 | Â | |
CentriMag BVAD | 1 | 0 | 1 | Â |